F8 and hemorrhagic disease: Factor VIII (FVIII) replacement therapy employs either FVIII concentrates from blood plasma or, alternatively, recombinant human FVIII, which is the standard of care for managing hemophilia A, a genetic bleeding disorder caused by plasmatic deficiency of this procoagulant factor.